Clinical trials
Nasopharyngeal Carcinoma (NPC) clinical trials
Below are recruiting nasopharyngeal carcinoma (npc) clinical trials, each written for real people, not researchers. We’re tracking 90 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06870435Recruiting
Screening for nasopharyngeal cancer with blood tests
This study compares three different blood tests to see which works best for spotting nasopharyngeal cancer early in people at higher risk. If you live in certain areas of China, you may be able to join.
Zhuhai, GuangdongAges 30–69 - NCT07303023RecruitingPhase 3
Personalized neck radiation to prevent cancer spread
This trial tests whether a personalized radiation plan for the neck can prevent cancer from spreading in people with nasopharyngeal carcinoma. It's for those whose cancer hasn't spread beyond the head and neck area.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT06912698RecruitingPhase 3
Lower vs. standard radiation for early nasopharyngeal cancer
This trial compares a lower dose of radiation to the standard dose for people with early-stage nasopharyngeal cancer. It aims to see if a lower dose is just as effective while reducing side effects.
Guangzhou, GuangdongAges 18–70 - NCT07188584RecruitingPhase 3
Smaller radiation vs. standard after chemo-immunotherapy for advanced nasopharyngeal cancer
This trial tests whether a smaller radiation treatment area is as effective as the usual larger one for people whose metastatic nasopharyngeal cancer has responded well to first-line chemotherapy plus immunotherapy. It aims to reduce side effects while keeping the cancer under control.
ZhuhaiAges 18–70 - NCT07154069RecruitingPhase 3
Immunotherapy for advanced nasopharyngeal cancer after chemo
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
Guangzhou, GuangdongAges 18–65 - NCT07137052Recruiting
Precise adaptive radiotherapy for nasopharyngeal cancer
This trial tests a more precise form of radiation therapy (adaptive radiotherapy) for nasopharyngeal cancer. It is designed for patients who have not yet had any treatment and whose cancer is limited to the head and neck area.
XiamenAges 18–70 - NCT07101744RecruitingPhase 2
Drug combination study for advanced nasopharyngeal cancer
This trial tests a combination of three drugs for people with nasopharyngeal cancer that has come back or spread and stopped responding to first-line chemotherapy. It aims to see if this new combination can help when standard treatment no longer works.
GuangdongAges 18–70 - NCT07085988RecruitingPhase 2
Nutrition help for nasopharyngeal cancer patients on chemoradiation
This trial tests if special nutritional management during concurrent chemoradiotherapy can improve outcomes for people with nasopharyngeal cancer. If you are getting both chemotherapy and radiation as your main treatment, this study may help you maintain better nutrition.
Nanchang, JiangxiAges 18 years+ - NCT07072143Recruiting
Study on children with rare tumors
This study is looking at children and teens with very rare tumors to learn more about these conditions and improve future care. It aims to gather information from patients treated at participating centers.
Padova, ItalyAges birth–18 years - NCT06749899RecruitingPhase 3
Immunotherapy with chemoradiation for advanced nasopharyngeal cancer
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
Fuzhou, FujianAges 18–65 - NCT06982300RecruitingPhase 1/Phase 2
PET scan for advanced nasopharyngeal cancer
This trial tests a special PET scan that can detect a receptor (SSTR2) on cancer cells to see if it can help guide treatment for people with nasopharyngeal cancer (a type of head and neck cancer). It may help doctors choose the best therapy for you.
GroningenAges 18 years+ - NCT06839066RecruitingPhase 2
HLX43 for advanced nasopharyngeal cancer after prior treatments
This trial tests an investigational drug called HLX43 for people with nasopharyngeal cancer that has come back or spread, and who have already tried two or more prior treatments without success. The goal is to see if HLX43 can shrink tumors or slow the cancer's growth.
Fuzhou, FujianAges 18 years+ - NCT05147844RecruitingPhase 2
Toripalimab plus radiation for limited-spread nose cancer
This Phase 2 trial studies whether adding toripalimab (an immune therapy) to radiation can control nasopharyngeal cancer that has spread only to a few places. It may help by boosting the immune system while the radiation treats the tumor sites.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06802835RecruitingPhase 1/Phase 2
EGFR antibody plus immunotherapy and chemo for advanced nasopharyngeal cancer
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Guangzhou, GuangdongAges 18–75 - NCT06787456Recruiting
Screening for nasopharyngeal cancer in residents
This study is screening residents aged 30-69 for nasopharyngeal cancer (NPC). It aims to detect cancer early through regular check-ups and follow-up.
Zhuhai, GuangdongAges 30–69 - NCT06763640Enrolling by invitation
TILs as a predictor in nasopharyngeal cancer
This study looks at how immune cells called TILs (tumor-infiltrating lymphocytes) in your tumor tissue might predict outcomes for nasopharyngeal cancer. It may help doctors better understand your cancer and guide future treatment decisions.
Nanchang, JiangxiAges 18–70 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06323239RecruitingPhase 2
Radiation plus chemo and immunotherapy for advanced nasopharyngeal cancer
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT06277050RecruitingPhase 3
Toripalimab and capecitabine after chemo-radiation for high-risk nasopharyngeal cancer
This trial tests whether adding the immunotherapy drug toripalimab to the chemotherapy pill capecitabine after standard treatment helps prevent nasopharyngeal cancer from coming back. It is for people with high-risk features who have already had chemo and radiation.
Ganzhou, JiangxiAges 18–70 - NCT06197776Recruiting
Predicting treatment success for advanced nasopharyngeal cancer
This study uses advanced testing (multi-omics) to predict if combining chemoradiation with immunotherapy works better for nasopharyngeal cancer that has returned or spread. It aims to find the right treatment for each person.
Guangzhou, GuangdongAges 18–70 - NCT06093061RecruitingPhase 2
Maintenance therapy for high-risk nasopharyngeal cancer
This trial tests a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and capecitabine (a chemo pill taken daily)—as maintenance therapy after initial chemotherapy for high-risk nasopharyngeal cancer. The goal is to see if this approach can lower the chance of cancer coming back.
SingaporeAges 21–99 - NCT06064097RecruitingPhase 2
Nivolumab plus chemo for young people with nasopharyngeal cancer
This trial tests combining the immunotherapy drug nivolumab with standard chemotherapy to treat newly diagnosed nasopharyngeal cancer in children and young adults. The goal is to see if adding this immune-boosting medicine can help shrink tumors and prevent the cancer from coming back.
Birmingham, AlabamaAges Up to 21 years - NCT06029270RecruitingPhase 2
Adding relatlimab to standard immunotherapy for nasopharyngeal cancer
This trial tests whether adding a new drug called relatlimab to the usual immunotherapy (nivolumab) helps people with nasopharyngeal cancer that has returned or spread. You will get standard chemotherapy plus nivolumab first, then if it works, you may be randomly assigned to get nivolumab alone or with relatlimab.
Dublin, CaliforniaAges 18 years+
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nasopharyngeal carcinoma (npc)?
- Yes. Clin2 currently lists 90 recruiting nasopharyngeal carcinoma (npc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nasopharyngeal carcinoma (npc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nasopharyngeal carcinoma (npc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.